Company founded by Shkreli off the hook in $43 million lawsuit: judge

NEW YORK (Reuters) - Vyera Pharmaceuticals, formerly known as Turing Pharmaceuticals, does not have to pay Impax Laboratories Inc $43 million in a dispute stemming from Turing founder Martin Shkreli's decision to boost by 5,000 percent the price of a drug Turing bought from Impax, a U.S. judge ruled on Friday.

Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

(Reuters) - Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.

One episode of postpartum depression raises likelihood of more

(Reuters Health) - Depression after giving birth is rare among women with no history of psychiatric disorders, but once “postpartum depression” occurs, the odds are much higher that it will happen again after subsequent births, researchers say.

One million unvaccinated Venezuelan kids vulnerable in measles outbreak: doctors

CARACAS (Reuters) - Around 1 million unvaccinated Venezuelan children are susceptible to measles, a highly contagious disease that has re-emerged in the crisis-stricken South American nation, a group of doctors estimated on Friday.

FDA proposes 1-1/2-year delay to nutrition label changes

(Reuters) - The U.S. Food and Drug Administration on Friday proposed giving manufacturers an extra 1-1/2 years to comply with new nutrition label requirements on packaged foods.

FDA approves Novo Nordisk fast-acting insulin Fiasp

(Reuters) - The U.S. Food and Drug Administration on Friday approved Novo Nordisk's fast-acting insulin to treat diabetes.

Home blood pressure monitoring works best with extra support

(Reuters Health) - People who monitor their own blood pressure at home may get better results if they also have extra support like counseling and lifestyle coaching, a research review suggests.

U.S. invests $170 million in late-stage Ebola vaccines, drugs

CHICAGO (Reuters) - The U.S. government is investing more than $170 million to help two new vaccines against the Ebola virus and two Ebola drugs complete the steps needed for approval from the Food and Drug Administration.

Medicare patients face high costs for newer injected cholesterol drugs

(Reuters Health) - Newer injected cholesterol medicines known as PCSK9 inhibitors can cost Medicare patients more than $300 a month, compared with only about $4 for older statin pills to lower cholesterol, a U.S. study suggests.

U.S. judge clears way for Maryland drug price-gouging law

(Reuters) - A U.S. District Court judge on Friday cleared the way for Maryland to implement the nation's first law designed to penalize drugmakers for price gouging by denying the generic drug industry trade group's request for an injunction.

Judge clears way for Maryland drug price-gouging law

(Reuters) - A U.S. District Court judge on Friday cleared the way for Maryland to implement the nation's first law designed to penalize drugmakers for price gouging by denying the generic drug industry trade group's request for an injunction.

US invests $170 million in late-stage Ebola vaccines, drugs

CHICAGO (Reuters) - The U.S. government is investing more than $170 million to help two new vaccines against the Ebola virus and two Ebola drugs complete the steps needed for approval from the Food and Drug Administration.

U.S. FDA proposes 1-1/2-year delay to nutrition label changes

(Reuters) - The U.S. Food and Drug Administration on Friday proposed giving manufacturers an extra 1-1/2 years to comply with new nutrition label requirements on packaged foods.